Results show that the relative expression of ITGB2 mRNA in the patient-derived ovarian cancer cell (PDC3) was 1.625, which was significantly upregulated (p = 0.0304 < 0.05) compared with the expression in the IOSE80 cell (mRNA = 1). This evidence concerns the gene ITGB2 and ovarian carcinoma.